Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

Parker Institute gathers its investigators’ cell therapy technologies into cancer cell therapy newco ArsenalBio

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell therapy for solid tumors.

Arsenal Biosciences Inc. is among the first disclosed companies to originate from the Parker Institute for Cancer Immunotherapy (PICI) as an extension of its aim to bring investigators and technologies from different academic research centers under one roof.

The institute has invested in and partnered with

Read the full 847 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE